Skip to main content

Table 2 Operative and postoperative data

From: ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study

Variables

ALPPS vs. TSH/PVE analysis

ALPPS (n = 21)

TSH/PVE (n = 37)

p value

Operative data step 1

 Operative time step 1 (minutes)

270 (215–303)

195 (145–250)

.001

 Operative procedure step 1, n (%)

  

n.a.

  Left atypical

0

23 (62)

 

  Left lateral resection

0

7 (19)

 

  Right atypical

0

2 (5)

 

  Right posterior resection

0

1 (3)

 

  Right hepatectomy

6 (29)

2 (5)

 

  Right hepatectomy plus atypical left

4 (19)

0

 

  Right hepatectomy plus left lateral resection

1 (5)

0

 

  Extended right hepatectomy

3 (14)

0

 

  Extended right plus atypical left

2 (10)

0

 

  Right trisectionectomy

4 (19)

0

 

  Right trisectionectomy plus atypical left

1 (5)

0

 

  Others

0

2 (5)

 

 Intraoperative blood transfusion step 1 (y/n)

7 (33)/14 (67)

6 (16)/31 (84)

.133

Inter-stage data

 Time interval between the stages (days)

10 (8–14)

57 (34–113)

< .001

 Inter-stage chemotherapy (y/n)

0

9 (24)

.014

 Inter-stage PVE (y/n)

0

27 (73)

< .001

 Rate of completion, n (%)

20 (95)

34 (92)

.629

 Reason for non-completion, n (%)

  

.323

  Insufficient hypertrophy

1 (100)

2 (67)

 

  Progressive disease

0

1 (33)

 

Operative data step 2

 Operative time step 2 (minutes)

123 (94–170)

280 (240–319)

< .001

 Operative procedure step 2, n (%)

   

  ALPPS completion

20 (100)

0

 

  Monosegment resection

0

1 (3)

 

  Left atypical

0

1 (3)

 

  Left hepatectomy

0

1 (3)

 

  Extended left hepatectomy

0

1 (3)

 

  Right atypical

0

2 (6)

 

  Right posterior resection

0

2 (6)

 

  Right hepatectomy

0

17 (50)

 

  Extended right hepatectomy

0

7 (21)

 

  Right trisectionectomy

0

2 (6)

 

 Intraoperative blood transfusion step 2 (y/n)

11 (55)/9 (5)

14 (41)/20 (59)

.325

Volumetric data

 Stage 1

   

  TLV (ml)

1672 (1589–2127)

1574 (1366–1801)

.046

  TV (ml)

45 (19–342)

23 (13–60)

.077

  FLR (ml)

534 (392–716)

450 (378–560)

.364

  cFLR (%)

29 (25–37)

29 (25–36)

.869

 Stage 2

   

  TLV (ml)

2083 (1724–2399)

1679 (1406–1775)

< .001

  TV (ml)

35 (19–103)

26 (13–68)

.208

  FLR (ml)

716 (504–954)

655 (486–744)

.448

  cFLR (%)

37 (30–47)

31 (33–50)

.103

 Degree of hypertrophy (%)

35 (23–62)

45 (18–69)

.803

Postoperative data

 Intensive care step 1, days

1 (1–2)

0 (0–1)

< .001

 Intensive care step 2, days

1 (0–1)

1 (1–1)

.044

 Hospitalization step 1 and 2, days

32 (22–46)

22 (17–28)

.009

 Clavien-Dindo stage 1 ≥ IIIa, n (%)

2 (10)

5 (14)

.654

 Clavien-Dindo stage 1 = V, n (%)

0

0

n.a.

 Clavien-Dindo stage 2 ≥ IIIa, n (%)

13 (65)

13 (38)

.057

 Clavien-Dindo stage 2 = V, n (%)

2 (10)

2 (6)

.577

Follow-up data

 R0 resection

20 (100)

30 (88)

.116

 Median RFS (95% CI), months

19 (8–30)

10 (6–14)

.050

 Median OS (95% CI), months

28 (19–37)

34 (25–43)

.963

  1. Data presented as median and interquartile range if not noted otherwise. Categorical data were compared using the chi-squared test, Fisher’s exact test, or linear-by-linear association according to scale and number of cases. Data derived from continuous variables of different groups were compared by Mann-Whitney U test. Oncological survival was compared by the log-rank test. Survival data were calculated under exclusion of perioperative mortality
  2. ALPPS associating liver partition and portal vein ligation for staged hepatectomy, cFLR calculated future liver remnant, FLR future liver remnant, OS overall survival, PVE portal vein embolization, RFS recurrence-free survival, TLV total liver volume, TV tumor volume